Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program
Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program
Shots:
- Novartis to get an option on Iconic’s ophthalmology program in exchange for an up front payment and equity investment in Iconic
- Iconic is evaluating its anti-Tissue Factor monoclonal antibody, ICON-4 for the treatment of age-related macular degeneration and plans the onset of clinical studies in 2020
- Iconic Therapeutics targets Tissue Factor biology to develop new therapies that bind to and antagonize Tissue factor in retinal diseases, cancer and other diseases where Tissue Factor is overexpressed
Click here to read full press release/ article | Ref: Iconic Therapeutics | Image: Elmvc